

PRECEPTORSHIP PROGRAMME

Immuno-Oncology

From the essentials of tumour
immunology to clinical application

**ESMO VIRTUAL
PRECEPTORSHIP**

18-19 NOVEMBER 2020

Co-Chairs

John B.A.G. Haanen, Netherlands
Ross A. Soo, Singapore

ESMO VIRTUAL PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY

From the essentials of tumour immunology to clinical application

18-19 November 2020

CO-CHAIRS:

John B.A.G. Haanen, Netherlands
Ross A. Soo, Singapore

SPEAKERS:

Cheng Ean Chee, Singapore
Jayesh Desai, Australia
Boon Cher Goh, Singapore
Alena Gros, Spain
Ravindran Kanesvaran, Singapore
Soo Chin Lee, Singapore

Brigette Ma, Hong Kong
Kenneth John O'Byrne, Australia
Solange Peters, Switzerland
Michele Teng, Australia
Baiyan Wang, China

LEARNING OBJECTIVES

- To understand the basics of tumour immunology
- To learn about the essentials of immunotherapies and their present indication in cancer treatment
- To learn about the status of development and clinical experience of immunotherapy in different tumour types

ACCREDITATION

The programme of this event has been accredited with **6 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



All timings are to be considered GMT+8

Wednesday, 18 November 2020

15:00-15:05 5'	Welcome	John B.A.G. Haanen, NL
15:05-15:45 40'	SESSION 1 Introduction	Chair/Moderator: John B.A.G. Haanen, NL
15'	Principles of tumour immunology: Explaining cellular immunity and immune surveillance	Michele Teng, AU
15'	Principles of cancer immunotherapy	Alena Gros, ES
10'	Discussion	Faculty
15:45-16:40 55'	SESSION 2 Recent advances with ICPI: Results in approved/unapproved indication – part 1	Chair/Moderator: Ross A. Soo, SG
15'	Melanoma advanced and adjuvant	John B.A.G. Haanen, NL
15'	Non-Small-Cell Lung Cancer	Ross A. Soo, SG
15'	Gynaecological malignancies and breast cancer	Soo Chin Lee, SG
10'	Discussion	Faculty
16:40-16:50	Break	
16:50-17:45 55'	SESSION 3 Clinical issues – part 1	Chair/Moderator: John B.A.G. Haanen, NL
15'	Assessment of efficacy	Kenneth John O'Byrne, AU
15'	Immune related toxicities and management	John B.A.G. Haanen, NL
15'	Biomarkers: PD-L1 and beyond PD-L1	Boon Cher Goh, SG
10'	Discussion	Faculty
17:45-18:25 40'	SESSION 4 Audience cases	Chair/Moderator: John B.A.G. Haanen, NL Ross A. Soo, SG
40'	Participants clinical case discussion (4x10')	Faculty

Thursday, 19 November 2020

15:00-15:55 55'	SESSION 5 Recent advances with ICPI: Results in approved/unapproved indication – part 2	Chair/Moderator: Ross A. Soo, SG
15'	Oesophageal, gastric and colorectal cancer	Jayesh Desai, AU
15'	Hepatocellular carcinoma (HCC)	Cheng Ean Chee, SG
15'	Head and neck cancer	Brigette Ma, HK
10'	Discussion	Faculty
15:55-16:20 25'	SESSION 6 Recent advances with ICPI: Results in approved/unapproved indication – part 3	Chair/Moderator: John B.A.G. Haanen, NL
15'	Advanced urinary cancer (renal and bladder)	Ravindran Kanesvaran, SG
10'	Discussion	Faculty
16:20-16:30	Break	
16:30-17:40 70'	SESSION 7 Audience cases	Chair/Moderator: John B.A.G. Haanen, NL Ross A. Soo, SG
70'	Participants clinical case discussion (7x10')	Faculty
17:40-18:05 25'	SESSION 8 Future of immuno-oncology	Chair/Moderator: Ross A. Soo, SG
15'	CAR T-Cell therapy	Baiyan Wang, CN
10'	Discussion	Faculty
18:05-18:30 25'	SESSION 9 Clinical issues – part 2	Chair/Moderator: John B.A.G. Haanen, NL
15'	Balancing costs and clinical benefit in medical oncology	Solange Peters, CH
10'	Discussion	Faculty
18:30-18:35 5'	Closure and farewell	John B.A.G. Haanen, NL Ross A. Soo, SG

Note: Each 10-minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion